BioNTech SE (BNTX) Accounts Payables (2018 - 2025)

BioNTech SE (BNTX) has 8 years of Accounts Payables data on file, last reported at $622.6 million in Q4 2025.

• In Q4 2025, Accounts Payables rose 36.55% year-over-year to $622.6 million; the TTM figure through Dec 2025 stood at $622.6 million (up 36.55% YoY), while the FY2025 annual figure was $604.3 million, up 32.54% from the prior year.
• Accounts Payables grew to $622.6 million in Q4 2025, from $467.4 million in the prior quarter.
• Across five years, Accounts Payables topped out at $949.3 million in Q2 2024 and bottomed at $32.1 million in Q1 2023.
• A 5-year average of $381.5 million and a median of $317.6 million in 2024 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2023 — Accounts Payables plunged 76.88% — and 2024, when it soared 911.45%.
• Year by year, Accounts Payables stood at $183.0 million in 2021, then increased by 13.77% to $208.2 million in 2022, then surged by 82.91% to $380.9 million in 2023, then grew by 19.71% to $456.0 million in 2024, then jumped by 36.55% to $622.6 million in 2025.
• The last three Accounts Payables figures came in at $622.6 million (Q4 2025), $467.4 million (Q3 2025), and $570.7 million (Q2 2025), per Business Quant data.

Peer Comparison